Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
Phase 3 Recruiting Network
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
- Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn, California
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
Phase 3 Recruiting Network
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are consid…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05561387
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Marshall Cancer Center — Cameron Park, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
Phase 3 Recruiting Industry
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years …
Sponsor: Pfizer
NCT ID: NCT06152575
Sites in California: - Beverly Hills Cancer Center — Beverly Hills, California
- Clovis Community Medical Center — Clovis, California
- Community Cancer Institute — Clovis, California
- Clinical Research Advisors (Encino Satellite Location) — Encino, California
- University of California San Francisco — Fresno, California
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexam…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05552222
Sites in California: - UCSF Fresno — Clovis, California
- City of Hope Duarte — Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- Valkyrie Clinical Trials — Los Angeles, California
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple m…
Sponsor: Celgene
NCT ID: NCT05519085
Sites in California: - Cancer and Blood Specialty Clinic — Los Alamitos, California
- Sharp Memorial Hospital — San Diego, California
- Local Institution - 0273 — West Hollywood, California
Phase 3 Recruiting Industry
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, inclu…
Sponsor: Kite, A Gilead Company
NCT ID: NCT06413498
Sites in California: - City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
- USC/Norris Comprehensive Cancer Center — Los Angeles, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- UC San Diego Moores Cancer Center — San Diego, California
- University of California San Francisco Medical Center — San Francisco, California
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dex…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06208150
Sites in California: - UCSF Fresno — Clovis, California
- UCLA — Santa Monica, California
Phase 3 Recruiting Industry
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…
Sponsor: AbbVie
NCT ID: NCT06158841
Sites in California: - Alta Bates Summit Medical Center for Research /ID# 261438 — Berkeley, California
- Providence - St. Jude Medical Center /ID# 262031 — Fullerton, California
- VA Loma Linda Healthcare System /ID# 261015 — Loma Linda, California
- Cedars-Sinai Medical Center /ID# 261008 — Los Angeles, California
Phase 3 Recruiting Industry
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, …
Sponsor: AstraZeneca
NCT ID: NCT07391657
Sites in California: - Research Site — La Jolla, California
- Research Site — Santa Monica, California
Phase 3 Recruiting Network
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as …
Sponsor: European Myeloma Network B.V.
NCT ID: NCT05243797
Sites in California: - UCLA Medical Center — Los Angeles, California
- University of California-Davis Cancer Center — Sacramento, California
- University of California, San Diego (UCSD) Medical Center — San Diego, California
Phase 3 Recruiting Industry
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dex…
Sponsor: Pfizer
NCT ID: NCT05020236
Sites in California: - Clovis Community Medical Center — Clovis, California
- Community Cancer Institute — Clovis, California
- University of California San Francisco — Fresno, California
- Community Regional Medical Center — Fresno, California
Phase 3 Recruiting Industry
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
Sponsor: GlaxoSmithKline
NCT ID: NCT06679101
Sites in California: - GSK Investigational Site — Beverly Hills, California
- GSK Investigational Site — Pasadena, California
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06615479
Sites in California: - UCLA Hematology/Oncology - Santa Monica — Los Angeles, California
- Local Institution - 0050 — Orange, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07258511
Sites in California: - USC Norris Comprehensive Cancer Center — Los Angeles, California
Phase 3 Recruiting Industry
This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05730036
Sites in California: - University of California Los Angeles (UCLA) — Los Angeles, California
Phase 3 Recruiting Industry
Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multip…
Sponsor: Takeda
NCT ID: NCT06980480
Sites in California: - Chao Family Comprehensive Cancer Center UCI — Orange, California
Phase 3 Recruiting Industry
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, …
Sponsor: Grifols Therapeutics LLC
NCT ID: NCT05645107
Sites in California: - GC2202 Study Site 115 — Huntington Park, California
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in California: - Sutter Auburn — Auburn, California
- Sutter Alta Bates — Berkeley, California
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate — Los Angeles, California
- Kaiser Permanente - Oakland Medical Center — Oakland, California
- Sutter Palo Alto Medical Foundation: Palo Alto — Palo Alto, California
Phase 2 Recruiting NIH
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06179888
Sites in California: - UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- Cedars Sinai Medical Center — Los Angeles, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06297226
Sites in California: - UCLA Hematology/Oncology - Westwood (Building 200 Suite 214) — Los Angeles, California
- UCSF Helen Diller Medical Center at Parnassus Heights — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Sponsor: AstraZeneca
NCT ID: NCT05850234
Sites in California: - Research Site — La Jolla, California
- Research Site — Los Angeles, California
- Research Site — San Francisco, California
Phase 2 Recruiting Industry
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants w…
Sponsor: Sanofi
NCT ID: NCT06356571
Sites in California: - Los Angeles Hematology Oncology Medical Group- Site Number : 8400027 — Los Angeles, California
- Private Practice - Dr. James R. Berenson- Site Number : 8400044 — West Hollywood, California
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in California: - Hoag Family Cancer Center — Newport Beach, California
- Stanford University — Palo Alto, California
Phase 2 Recruiting Industry
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called r…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07266441
Sites in California: - City of Hope — Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- University of California San Francisco — San Francisco, California